Chime Financial, Inc. (CHYM) Stock Price & How to Invest

Chime is a financial technology company, not a bank. It runs a mobile app that gives roughly 10.4 million active members a checking-style spending account, a savings account, a secured credit builder card, fee-free overdraft (SpotMe), early wage access (MyPay), small Instant Loans and, since 2026, a commission-free investing product (Chime Invest). The actual deposit accounts sit at two partner institutions, The Bancorp Bank and Stride Bank, both small enough to be exempt from the Durbin Amendment's interchange caps. That exemption is the economic engine: Chime keeps a share of the interchange fee merchants pay every time a member swipes, which is why the company can charge no monthly fee, no minimum balance and no overdraft fee and still book an 89% gross margin. Payments revenue was about $430 million of the $670 million booked in the second quarter of 2026, with the remaining $240 million coming from platform-related products like MyPay and Instant Loans, and that second bucket is growing far faster (roughly 48% year over year against 17%).

The investment picture changed in 2026. Chime went public in June 2025 at $27 a share, valuing it near $11.6 billion, less than half the $25 billion it carried in its last private round, and the stock spent most of its first year drifting (down about 24% over the twelve months to August 2026). Then the numbers turned: GAAP net income of about $53 million in Q1 2026 and about $28 million in Q2 2026, adjusted EBITDA of $102 million on a 15% margin (up more than 12 percentage points year over year), and revenue growth accelerating from 25% to 27%. The catalyst management points to is Chime Prime, a free premium tier launched in April 2026 that unlocks 5% category cash back, 3.75% APY savings and travel perks for members depositing at least $3,000 a month; Prime members generate more than twice the average revenue per member. Full-year 2026 revenue guidance was raised to $2.725 billion to $2.745 billion and adjusted EBITDA guidance to $465 million to $475 million. The complicating details are a 10% workforce reduction (about 150 roles) announced in late July as the company restructures around AI, and a CFO transition, with Matt Newcomb departing on August 7, 2026 and Mark Troughton stepping in on an interim basis.

The largest risk is regulatory and sits outside the company's control: Chime's economics depend on partner banks staying exempt from the Durbin Amendment's debit interchange caps, and any move to extend those caps to sponsor-bank arrangements would compress the majority of revenue quickly. Bank-as-a-service partnerships carry their own supervisory scrutiny, and Chime does not hold its own charter, so a problem at The Bancorp Bank or Stride Bank becomes Chime's problem. Earned wage access rules have swung twice at the federal level and remain a patchwork at the state level, which makes MyPay's future treatment genuinely uncertain. GAAP profitability is new and thin (about $28 million on $670 million of quarterly revenue, with trailing twelve-month net income still slightly negative), so the valuation rests on forward estimates rather than a track record, and the stock trades near 47 times forward earnings. A consumer class action filed in April 2026 over a data breach that locked members out of accounts is pending, the chief financial officer departed on August 7, 2026, and the company cut about 10% of staff a week before reporting, all of which are execution questions rather than settled facts. Shares have moved more than 20% in a single session on results, so position sizing tends to reflect that volatility.

20 analysts publish price targets on CHYM, averaging $30.35 against a $31.25 price as of August 2026, or -2.9%. The published targets run from $21.00 to $40.00, a moderate spread, and the ratings split 17 buy, 3 hold, 0 sell. Over the last six months there have been 7 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full CHYM forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Chime Financial, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Chime Prime lifting revenue per member. For years the bear case on Chime was that revenue per active member was stuck around $250 while member counts grew. The most optimistic published target, $40.00, assumes this works close to its best case.

The case against. The largest risk is regulatory and sits outside the company's control: Chime's economics depend on partner banks staying exempt from the Durbin Amendment's debit interchange caps, and any move to extend those caps to sponsor-bank arrangements would compress the majority of revenue quickly. The most pessimistic target, $21.00, is roughly what CHYM is worth if this bites instead.

Read the full bull and bear case on CHYM, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Chime Financial, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$2.46 billion, up ~26% year over year
• Q2 2026 revenue: ~$670 million, up ~27%, with full-year 2026 guided to ~$2.73-2.75 billion
• Active members / ARPAM: ~10.4 million (up ~20%), ~$260 average revenue per active member
• Adjusted EBITDA: ~$102 million in Q2 2026 (~15% margin), full year guided to ~$465-475 million
• GAAP net income: ~$28 million in Q2 2026, a second straight profitable quarter, but ~-$18 million trailing twelve months
• Market cap / forward P/E: ~$12 billion at ~$31 a share, ~47x forward earnings

Chime screens as a growth fintech rather than a bank, and the multiple reflects that: at roughly 4.5 times forward revenue and about 47 times forward earnings, it prices well above any deposit-taking institution and closer to a software company with mid-20s growth. The trailing price-to-earnings ratio is not meaningful because trailing net income is still marginally negative, distorted by stock compensation tied to the 2025 IPO. Investors comparing Chime to SoFi or Dave usually anchor on revenue multiples and ARPAM trajectory instead, since the reported margin structure (89% gross margin, 73% transaction margin) does not translate into bank comparables.

Other names that sit close to CHYM: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get CHYM exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so CHYM sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where CHYM fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Chime is a scaled consumer banking app that has finally turned the corner on profitability, priced on the assumption that member growth and revenue per member both keep climbing.

Whether CHYM is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CHYM a buy or a sell?, and where the stock could go from here in the CHYM stock forecast.

For income investors, whether CHYM pays a dividend and how the payout looks is covered in does CHYM pay a dividend? And to weigh CHYM against a peer, read the full side-by-side comparisons: CHYM vs DAVE and CHYM vs SOFI.